一脉阳光(02522.HK)拟收购高脉健康70.0%股权

Core Viewpoint - The company Yimai Sunshine (02522.HK) has announced the acquisition of a 70% stake in Gaomai Health for a total consideration of RMB 54 million, enhancing its position in the nuclear medicine imaging sector [1][2]. Group 1: Acquisition Details - Yimai Sunshine Health Management will acquire 30%, 20%, and 20% stakes in Gaomai Health from three sellers, with the total transaction amounting to RMB 54 million [1]. - Following the acquisition, Gaomai Health will become a subsidiary of Yimai Sunshine, and its financial performance will be consolidated into the group's financial statements [1]. Group 2: Strategic Collaboration - The acquisition is part of a strategic collaboration with Seller I, aimed at leveraging each other's strengths in the nuclear medicine field [2]. - The partnership will focus on innovative business models, professional medical teams, and advanced specialized technologies to explore significant opportunities in the third-party medical imaging service industry [2]. Group 3: Operational Enhancements - The collaboration will enhance Yimai Sunshine's capabilities in developing, managing, and operating nuclear medicine projects, utilizing Seller I's extensive resources and expertise [3]. - Both parties will work together to promote the application of new radioactive drug synthesis in PET/CT services, enhancing precision diagnostic capabilities in nuclear medicine [3]. - The strategic direction includes expanding market presence for third-party medical imaging centers, developing regional nuclear medicine services, and exploring innovative imaging service products and AI in imaging diagnostics [3].